Drug Profile

MRx 4DP0004

Alternative Names: CJRB 402; MRx-0004; MRx-4DP0004

Latest Information Update: 07 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 4D Pharma PLC
Class Antiasthmatics; Antivirals; Bacteria
Mechanism of Action Bacteria replacements; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Asthma
Discontinued COVID 2019 infections

Most Recent Events

20 Jun 2023 4D pharma plc terminates phase-I/II clinical trial in Asthma in USA and United Kingdom (PO), due to sponsor insolvency (NCT03851250) (EudraCT2018-003242-16)
27 Mar 2023 CJ Biosciences acquires MRx 4DP0004 from 4D Pharma
13 Jul 2022 Efficacy and adverse event data from the phase I/II trial in Asthma presented at the 118^th International Conference of the American Thoracic Society (AST-2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com